Childhood aplastic anaemia (AA) is an uncommon but potentially fatal haematological disorder. Patients with AA receive supportive care based on transfusions and timely treatment of opportunistic infections, along with specific therapies, which may be bone marrow transplantation and immunosuppressive therapy. Early diagnosis and supportive therapy are required to prevent fatal complications like overwhelming sepsis or life threatening haemorrhages. We report two cases of aplastic anaemia having a different aetiology. The diagnostic work-up and the therapeutic management for each case are described below.
Introduction
Childhood aplastic anaemia (AA) is a rare but potentially fatal haematological disorder with an annual incidence of 2-6 per million in the USA and Europe [1, 2] and with a peak age of occurrence between 3 and 5 years. It is defined as a peripheral blood pancytopenia with a hypocellular bone marrow (BM) in the absence of abnormal infiltration or increased reticulin [3] . To diagnose AA at least two of the following three criteria must be satisfied: haemoglobin <100 g/l, platelet count <50 · 10 9 /l, neutrophil count <1.5 · 10 9 /l [4] . AA may be classified on the basis of severity ( Table 1) .
Many pathogenetic mechanisms have been proposed to explain the bone marrow failure seen in AA. In most cases, bone marrow failure results from an immune-mediated mechanism [5] which leads to T-cell activation [6] with subsequent secretion of inhibitory cytokines (such as IL-6, INTγ TNFα) determining the inhibition of proliferation and differentiation of haematopoietic progenitor cells and their death by apoptosis [7] . The event that determines T-cell activation remains unclear. Diverse polymorphisms in Th1 cytokine genes have been observed in patients with AA [8, 9] . Over-expression of HLA-DR2, which may regulate antigen recognition, has also been detected. These alterations suggest a genetic basis for the abnormal T-cell activation in bone marrow failure. In more than 30% of the patients with AA, no evidence has been advanced in support of an immune aetiology which points to the existence of additional pathophysiological mechanisms. In some patients with AA, an atypical telomere shortening in haematopoietic cells has been observed. The mutations in components of the telemorase complex may have a role in the aetiology of AA, inducing low telomerase activity and a subsequent reduction of proliferative capacity of haematopoietic precursors. Furthermore, the variety of clinical manifestations and the different responsiveness to the treatment seem to be related to specific several host genetic risk factors, environmental factors, and individual differences in the immune response pattern.
The disorder can be inherited or acquired. The causes include radiation therapy [10] , intake of drugs and chemicals [11] , viral infections [12] , thymoma [13] , pregnancy [14] and paroxysmal nocturnal hemoglobinuria [15] . Most cases of acquired AA are idiopathic ( Table 2) . Independently of the aetiology, severe AA constitutes an acute medical emergency: erythrocytes, granulocytes and platelets can rapidly decrease to low levels [16, 17] .
Early diagnosis and supportive therapy are needed to prevent fatal complications like overwhelming sepsis or life threatening haemorrhage.
We report two cases of aplastic anaemia having a different aetiology. The diagnostic work-up and the therapeutic management for each case are described.
Case report 1
An 8-year old girl was admitted to our department with diffuse ecchymosis that started one month earlier and had progressively increased.
Upon physical examination she showed a good performance status, pale skin, palpable submandibular and lateral cervical and axillary lymph nodes. Multiple ecchymosis was visible on the lower extremities and some petechias on the forearms and the periombelical region.
After Table 2 . Aetiology of aplastic anaemia.
Severity Criteria
Severe Bone marrow cellularity <25% (or 25-50% if <30% residual haemopoietic cells) and at least two of the following: Peripheral blood neutrophil count <0.5 · 10  Non-severe Hypocellular bone marrow with peripheral blood cytopenias not fulfilling criteria for severe or very severe aplastic anaemia Table 1 . Classification of aplastic anaemia according to severity.
was also found. The bone-marrow biopsy showed an aplastic anemia with a cellularity of 40%. Karyotyping revealed no abnormalities. A DEB test was carried out and the patient was also screened for paroxysmal nocturnal hemoglobinuria. The results obtained allowed genetic aetiology to be excluded and a diagnosis of idiopathic acquired aplastic anaemia to be made.
The patient underwent periodic blood examinations and required weekly supportive transfusional care. The haemoglobin was maintained at a level higher than 7g/ dl and platelets were prophylactically transfused for a blood count lower than <10·10 9 /l. To reduce the chance of alloimmunisation, the patient received leucocyte depleted blood products. Further, iron status was followed and when the ferritin level was >2500µg/l iron chelation was started. Furthermore, the child developed several infective episodes which were treated with broad-spectrum antibacterial therapy (combination of a glycopeptide and a carbapenem or third-generation cephalosporin).
Since an HLA compatible sibling donor for bone marrow transplantation (BMT) was not available, immunosuppressive therapy using the combination of antithimocyte globulin (ATG), cyclosporine and methyprednisolone was performed. The child did not respond to the first course of immunosuppressive treatment and continued to be transfusion-dependent. She underwent a second course of immunosuppressive therapy, achieving a partial response. At present the patient has been transfusion-independent for five months.
Case report 2
A 9 year old child had a 2 year long history of frequent epistaxis and petechias on the face and the trunk. At the age of three a congenital kidney malformation (horse shoe) was accidentally diagnosed. He was subjected to a thorough physical exam and laboratory investigations to determine his clinical condition. On examination he presented a good performance status, pale skin, a retro-auricular lymph node swelling approximately 1 cm in diameter, petechias bilaterally under-orbital and ecchymosis on the lower extremity. Haematological examination showed a peripheral blood pancytopenia: haemoglobin 9,1 g/dl; white cell count 3,160/mmc (neutrophils 720; lymphocytes 2,250, monocytes 130); platelets 21,000/mmc. Reticulocyte count was constantly 0.4%. The bone-marrow biopsy confirmed an aplastic anaemia. Karyotyping revealed no abnormalities. No active infection was found. The DEB test was positive and a diagnosis of Fanconi anaemia (FA) was formulated. No abnormalities were detected by skeleton X-rays.
After the diagnosis, the patient underwent periodic blood examination (about every three weeks) but never needed erythrocyte or platelet transfusions. Relatives were tested for chromosomal fragility to exclude the possibility there were hidden FA and studied for the purpose of finding an HLA compatible donor. Because no HLA-identical non-FA family donor was found, the child was deemed to be a candidate for BMT from an unrelated donor.
Discussion
Aplastic anaemia is a haematological disease with pancytopenia and marrow hypoplasia arising from a wide spectrum of diseases, including a variety of congenital marrow failure states and acquired aplastic anemia. Many conditions are present in children with pancytopenia, some of which may also feature a hypocellular marrow and extensive investigations are mandatory in order to exclude them. Infections represent the cause of 10-20% of pancytopenia in childhood [18] . To rule out an infectious agent, specific antibodies measurement is required although the presumed infectious cause of aplastic anemia are often not identified [19] .
Meticulous morphological, cytogenetic and immunophenotypic examinations of the peripheral blood and bone marrow must be performed to exclude myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), which is the most common haematological malignancy to occur with pancytopenia.
At diagnosis, all patients presenting pancytopenia and marrow hypoplasia should be screened for paroxysmal nocturnal hemoglobinuria clones with flow cytometry.
All children with AA should also be investigated for inherited marrow failure syndrome (IBMFS). Diagnosis of IBMFS such as Fanconi's anemia and dyskeratosis congenita may be obvious clinically although not in all cases because of clinical and genetic heterogeneity. Fanconi anemia generally occurs in infancy but if urogenital and skeletal abnormalities are not present, the diagnosis may be made in adulthood [20] . Specific tests are available to confirm any clinical suspicion: FA may be diagnosed by the demonstration of diepoxybutane (DEB)-induced chromosomal breakage in peripheral blood lymphocytes. Further, in some IBMFS specific genetic abnormalities may be identified that facilitate diagnosis (e.g. mutated C-MPL in amegakaryocytic thrombocytopenia).
In our cases, the two patients presented comparable clinic outcomes although the serial examinations performed allowed two different specific diagnoses to be formulated: case 1 may be considered an idiopathic anaemia; case 2 is a Fanconi anemia, which typifies the most common IBMFS. Congenital and acquired AA can lead to clinical similarities but the management and the treatment are quite different.
IBMFS management is complex and must be handled by specialist centres. Soon after diagnosis, the patients have to undergo a multidisciplinary monitoring programme aimed at identifying early signs of marrow failure as well as associated pathologies that can affect other organs and apparatus. Treatment of congenital AA may be variable, including progenitor cell transplantation from bone marrow, androgen corticosteroids, growth factors and gene therapy. Nowadays only transplantation is potentially curative, and further studies on target therapy are necessary.
According acquired AA, bone marrow transplantation (BMT) and immunosuppressive therapy (IST) are the main therapeutic modalities. The first choice for treatment in children with severe aplastic anemia is allogeneic bone marrow transplantation (BMT) from an HLA identical sibling donor. It is curative in the vast majority of young patients, estimated at about 80-95% of the cases [21] . Graft failure appears in 5-15% of cases; severe acute GVHD occurs rarely [22] . On the other hand, chronic GVHD represents the main complication in 30-40% of patients, and has an impact on the quality of life, secondary tumor onset and mortality [23, 24] .
Immunosuppressive therapy using the combination of antithymocyte globulin (ATG), cyclosporin and methyprednisolone is indicated for other children who have no HLA compatible sibling [25, 26] . Overall survival at 5 years is estimated at about 80%, but the eventfree survival rate is lower as a result of non response or relapse. Relapse, defined as requirement for platelet or erythrocyte transfusions in patients having been transfusion-independent for at least 3 months, occurs in about 30% of patients [27] . In addition, these patients have an increased risk of developing solid tumors and clonal disorders such as myelodysplastic syndromes (most frequently involving chromosomes 7 or 8), acute myeloid leukaemia and paroxysmal nocturnal hemoglobinuria [28] . Clonal evolution can occur several years after immunosuppressive therapy and necessitate a long follow-up of up to 10 years [29] . The rate is about 15% [30] and seems to be independent of response to immune-therapy. A second course of immunosuppressive therapy is indicated for non-responders or relapsing patients. The haematologic response rates after the second course are estimated at around 30-70% for nonresponders, whereas they are between 60 and 65% in relapsing patients [31] .
BMT from an unrelated donor for AA is indicated in patients with severe or very severe AA who are not eligible for sibling donor BMT and have not responded to at least two courses of ATG and cyclosporin (for children, at least one course).
In our cases, no compatible familiar donor was found for both patients: the child with acquired anemia underwent two courses of immunosuppressive therapy, with partial response while the patient with FA was listed for BMT from an unrelated donor. Along with specific therapies, it is mandatory that all patients with acquired or congenital AA receive adequate transfusional support to maintain safe blood counts and that opportunistic infections are promptly treated with systemic antibiotic drugs and early introduction of systemic antifungal drugs. Further, iron status should be monitored in order to detect any transfusion-related iron overload and relative complications. Although it represents a considerable individual variability, iron chelation should be started when the serum ferritin is > 2000-2500µg/l.
Haematopoietic growth factors, such as granulocyte or granulocyte-macrophage colony-stimulating factor (G-CSF/GM-CSF) might be used for patients with AA with symptomatic infection, although it has not been demonstrated that they can correct the primary stem-cell defect and influence the overall response and survival [32] . Only one of the two patients we described needed transfusional support and developed several infections that were quickly treated with systemic antibiotic.
Factor predicting response to IST and overall survival were not clearly identified. Improvements in blood count seem to be related to transfusion independence and to the absence of neutropenic infections. Recent studies have shown that baseline absolute lymphocyte and reticolocyte counts are good predictors [33] : patients with an absolute lymphocyte count of less than 1000/µL and an absolute reticulocyte count of less than 25000/ µL have a lower response rate and worse survival than those with a higher blood count. Better long-term prognosis is also related to the robustness of blood count recovery. Furthermore, patient age seems to influence ITS outcomes and overall survival: patients aged less than 18 years are more responsive to the treatment and survival is higher than 90% versus the 50% observed in adults over the age of 60 [34] .
The survival of paediatric patients with severe aplastic anemia has improved greatly over the last two decades as a result of the advances in human leukocyte antigen (HLA)-identical related haematopoietic stem cell transplantation (HSCT) and in immunosuppressive treatment (IST) as well as the improvements in transfusion support, antimicrobial treatment and general supportive care.
Conclusion
Aplastic anaemia is a rare haematological disease in childhood arising from inherited or acquired bone marrow failure. It should be suspected in children that present symptoms caused by pancytopenia, like bruising and mucosal bleeding or recurrent infections. Congenital and acquired AA may have a comparable clinical outcome related to pancytopenia severity although the management and therapy are different. Early diagnosis and specific treatment associated with supportive care are important in order to diminish the risks of morbidity and mortality in patients with AA.
